A detailed history of Goldman Sachs Group Inc transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 145,861 shares of ABOS stock, worth $269,842. This represents 0.0% of its overall portfolio holdings.

Number of Shares
145,861
Previous 51,052 185.71%
Holding current value
$269,842
Previous $123,000 193.5%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.22 - $3.54 $210,475 - $335,623
94,809 Added 185.71%
145,861 $361,000
Q2 2024

Aug 13, 2024

SELL
$2.14 - $4.01 $571,063 - $1.07 Million
-266,852 Reduced 83.94%
51,052 $123,000
Q1 2024

May 15, 2024

BUY
$2.97 - $4.64 $603,420 - $942,718
203,172 Added 177.08%
317,904 $1.29 Million
Q4 2023

Feb 13, 2024

BUY
$1.86 - $4.48 $106,825 - $257,299
57,433 Added 100.23%
114,732 $440,000
Q3 2023

May 14, 2024

SELL
$4.15 - $9.72 $238,346 - $558,248
-57,433 Reduced 50.06%
57,299 $237,000
Q3 2023

Nov 14, 2023

BUY
$4.15 - $9.72 $181,467 - $425,026
43,727 Added 322.19%
57,299 $237,000
Q2 2023

May 14, 2024

SELL
$3.59 - $6.59 $103,140 - $189,330
-28,730 Reduced 67.92%
13,572 $65,000
Q2 2023

Aug 14, 2023

SELL
$3.59 - $6.59 $103,140 - $189,330
-28,730 Reduced 67.92%
13,572 $65,000
Q1 2023

May 14, 2024

BUY
$3.75 - $6.65 $94,916 - $168,318
25,311 Added 148.97%
42,302 $171,000
Q1 2023

May 11, 2023

BUY
$3.75 - $6.65 $94,916 - $168,318
25,311 Added 148.97%
42,302 $171,000
Q4 2022

May 14, 2024

SELL
$4.81 - $10.17 $27,061 - $57,216
-5,626 Reduced 24.88%
16,991 $91,000
Q4 2022

Feb 13, 2023

SELL
$4.81 - $10.17 $27,061 - $57,216
-5,626 Reduced 24.88%
16,991 $91,000
Q3 2022

May 14, 2024

SELL
$4.44 - $10.48 $23,394 - $55,219
-5,269 Reduced 18.89%
22,617 $227,000
Q3 2022

Nov 10, 2022

SELL
$4.44 - $10.48 $23,394 - $55,219
-5,269 Reduced 18.89%
22,617 $0
Q2 2022

May 14, 2024

SELL
$3.08 - $4.88 $267,485 - $423,808
-86,846 Reduced 75.69%
27,886 $131,000
Q2 2022

Aug 15, 2022

SELL
$3.08 - $4.88 $943,431 - $1.49 Million
-306,309 Reduced 91.66%
27,886 $131,000
Q1 2022

May 16, 2022

BUY
$3.91 - $6.73 $42,740 - $73,565
10,931 Added 3.38%
334,195 $1.31 Million
Q4 2021

Feb 14, 2022

BUY
$6.54 - $15.31 $1.7 Million - $3.97 Million
259,629 Added 408.0%
323,264 $2.19 Million
Q3 2021

Nov 10, 2021

BUY
$14.5 - $20.28 $922,707 - $1.29 Million
63,635 New
63,635 $946,000

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $74.9M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.